srpt gene therapy - Search News

News

FDA asks Sarepta to stop shipping gene therapy

Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says

The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene therapy Elevidys, a source familiar with the matter told Reuters on Friday.

· 2d

Sarepta's Setback Deepens With Another Gene Therapy Fatality

· 2d · on MSN

Sarepta falls as report suggests FDA weighing a request to stop gene therapy shipments

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Seeking Alpha1y

Sarepta: Leading The Way In DMD Treatment With Gene Therapy Innovations ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biopharmaceutical company that develops Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy (LGMD) treatments using gene therapy, ...

Nasdaq4mon

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne ...

Insider Monkey6mon

Sarepta Therapeutics, Inc. (SRPT): Is This Gene Therapy Stock a Good ...

The cornerstone of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s recent success has been ELEVIDYS, a gene therapy approved by the FDA in June 2023, and later expanded in 2024 to treat ambulatory ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results